Dr RR Baliga's "Got Knowledge Doc" Podkast

🌸 Dōgen Zenji (1200–1253), founder of the Sōtō Zen school in Japan, taught that true practice lies in zazen—"just sitting" 🧘‍♂️ —where enlightenment and practice are inseparable. His  Shōbōgenzō continues to inspire mindfulness & presence today. ⏳✨ #Zen #Mindfulness

🚨 New Evidence in NSTEMI Care! 🫀 The SLIM Trial shows that FFR-guided complete revascularization during the index procedure in patients with NSTEMI and multivessel disease significantly reduces death, MI, stroke, and repeat PCI compared to culprit-only PCI.   🎯 Key win? Fewer revascularizations, better outcomes — physiology beats anatomy again.   📚 Published in JAMA , presented at #ESC2025 🔗...

💥 Practice-Changing Evidence in HFpEF! 💥 In a real-world cohort of 97,000+ patients with obesity & type 2 diabetes, semaglutide and tirzepatide reduced risk of heart failure hospitalization or death by over 40% 📉 ⚖️ No meaningful difference between the two agents. 🧠 Findings reinforce STEP-HFpEF & SUMMIT trials and highlight GLP-1 therapies' expanding role in cardiometabolic HFpEF 🫀 #Cardiolo...

📢 Just read the #AMALFI trial in JAMA 📰 — a landmark remote RCT of AF screening using 14-day ECG patches mailed to older adults at stroke risk 📦🫀. At 2.5 years, the patch group had a modestly higher AF detection rate (6.8% vs 5.4%, p=0.03) and increased anticoagulation use 💊🧠. Stroke rates were similar ⚖️.   🎯 Key takeaway: Remote, mail-based AF screening is feasible and nudges diagnosis ra...

🚨 New Trial Alert 🚨 Can we safely stop anticoagulation after AF ablation? The ALONE-AF Trial 🫀 suggests yes —in selected patients with no AF recurrence, stopping DOACs reduced major bleeding 🌟 without increasing stroke risk 🧠.   📉 0.3% vs 2.2% for the composite outcome (P = .02) 📍 Carefully monitored, low-risk patients may benefit most.   📝 Editorial: Recommends shared decision-making 🤝 &...

🚨 New Findings from the HELP-MI Trial! 🇸🇪🧪 Can routine Helicobacter pylori screening during acute myocardial infarction (MI) hospitalization prevent upper gastrointestinal bleeding (UGIB)?   💉 Over 18,000 patients across 35 Swedish hospitals 📉 Result: No significant reduction in UGIB overall (RR 0.90; P=0.18) 🔍 BUT: Clear benefit in patients with anemia (RR 0.44–0.64) and chronic kidney disea...

🩺 New Insights on Apixaban for VTE! 📢 The HI-PRO trial challenges the old 3-month rule for provoked VTE. 📉 Extended low-dose apixaban (2.5 mg BID) reduced recurrent VTE from 10.0% ➡️ 1.3% with minimal major bleeding. 🎯 Editorial in NEJM urges a shift from binary labels ("provoked vs unprovoked") to a patient-centered, risk-adapted approach. 🧠 Art meets evidence in the decision to extend antic...

🌏 Zhu Xi (1130–1200), a master of Neo-Confucianism , reshaped Chinese philosophy with his focus on rationality, self-cultivation & education . His commentaries on the Four Books guided civil service exams for centuries across East Asia. 📚✨   #Leadership #Philosophy #History #Confucianism

Just read the latest from NEJM? The PIpELINe Trial 🇮🇹 changes how we approach cardiac rehab in older adults post-MI! 🧓❤️ 🎯 A 12-month, multidomain intervention — risk factor control, nutrition 🥗, and Otago-based exercise 👟 — cut CV death/hospitalization from 20.6% → 12.6% (P=0.01)! 📉 Hospitalizations for heart failure dropped 7.1% → 1.5% . No serious adverse events. And yes — better gait spee...

🚨 New Meta-Analysis Alert! 💊🫀 Can β-blockers benefit patients post-MI with mildly reduced ejection fraction (LVEF 40–49%)?   📊 An individual patient data meta-analysis (REBOOT, BETAMI, DANBLOCK, CAPITAL-RCT) shows a 25% reduction in the composite outcome of death, MI, or HF with β-blockers vs. control (HR 0.75; p =0.031) — even in the absence of clinical heart failure.   🌍 Consistent across t...

🚫💊 Should We Rethink Beta-Blockers Post-MI? In the landmark REBOOT trial (NEJM, 2025), beta-blockers failed to reduce mortality, reinfarction, or heart failure hospitalizations in post-MI patients with preserved ejection fraction (>40%).   💡 A modern, pragmatic trial across 109 centers (Spain + Italy 🇪🇸🇮🇹) with 8438 patients — shaking the foundation of our long-held post-MI practices. 👩‍⚕️ Sig...

🚨 New NEJM Study Alert! 🩺💔 Do beta-blockers still help after a heart attack if there's no heart failure? 🤔   In the BETAMI–DANBLOCK trial (🇩🇰+🇳🇴, n=5574), beta-blocker therapy in post-MI patients with preserved or mildly reduced LVEF (≥40%) modestly reduced the composite outcome of death or major cardiovascular events 🧠📉   📌 Primary endpoint: 14.2% (BB) vs. 16.3% (no BB) → HR 0.85, p =0.03...

💥 New NEJM Trial Alert! A modest 0.3 mmol/L rise in potassium (via MRA, KCl, or diet) significantly reduced arrhythmias, ICD shocks, and hospitalizations in high-risk ICD patients ⚡🫀   📉 HR 0.76 for the composite endpoint 🔢 NNT = 12.3 over 3.3 years 🍌 Safe, scalable, and globally relevant   👉 Time to rethink "normal" K⁺ levels in cardiology! #Cardiology #Electrophysiology #NEJM #ICD #Potass...

🚨 New RCT Alert from the NEJM ! Can an old 💊 make a comeback in modern 💓 failure care?   📌 The DIGIT-HF trial showed that digitoxin , a cardiac glycoside with hepatic clearance, reduced the combined endpoint of all-cause death or HF hospitalization in HFrEF patients on contemporary guideline-directed therapy — including ARNI, beta-blockers, MRAs & SGLT2i. 🩺 HR = 0.82; p = 0.03 📉 👩‍⚕️ Safe i...

🚨 Calcific Aortic Valve Stenosis (CAVS): Beyond Wear and Tear 🫀🪨   Once thought to be "degenerative," CAVS is now recognized as an active disease driven by oxidative stress ⚡, inflammation 🔥, and lipoprotein(a) 🧬. Despite its growing global burden, no drug therapy slows its progression.   🩺 Current management: Surgical (SAVR) or Transcatheter (TAVR) valve replacement. 💊 Emerging hope: PCSK...

🚨 New in The Lancet (2025) 🚨 A mega meta-analysis of 484 RCTs (104K+ participants) offers a game-changing approach to hypertension management! 💊📉   Instead of guessing how much BP will drop, now you can predict it —by drug, dose, and combo! 🎯 Like statins for LDL, this study introduces low-, moderate-, and high-intensity BP regimens based on expected mmHg reductions. 💡   Use the free calcula...

🧒❤️ Partial Heart Transplant: A Growing Solution for Growing Hearts! 🌱🔬   🚨 Pediatric patients with congenital heart valve disease often face multiple surgeries due to non-living valve grafts that don't grow . This landmark study from @DukeHealth shows how living valves via partial heart transplant can change the game.   📊 In 19 patients (median age: 97 days), transplanted valves showed true...

🐖🫁 World First: Pig Lung Transplanted into Human 🧬🌍 In a groundbreaking step for xenotransplantation, a team in China successfully transplanted a genetically modified pig lung into a brain-dead human recipient. The lung functioned for 216 hours without hyperacute rejection, offering hope to thousands on organ waitlists.   🔬 Key breakthroughs: • 6-gene-edited donor pig • No Porcine Endogenous...

🧬 Pre-Heart Failure? Let Age Speak! 👵👴   New study in JACC compares fixed vs age-adjusted NT-proBNP cutoffs for defining pre–heart failure (Pre-HF) in over 22,000 adults across ARIC, MESA, and CHS cohorts.   📉 Key Insight : Age-adjusted cutoffs reduce overdiagnosis in older adults 🧓 and improve risk prediction for heart failure hospitalization 🏥.   📊 With better C-statistics, NRI, IDI , and...

🚨 Game-Changer in Lung Cancer! 🫁💉   The 5-year results from CheckMate 816 are in! Neoadjuvant nivolumab + chemotherapy significantly improved survival in resectable NSCLC 🎯   ✅ 65.4% 5-year OS vs. 55.0% with chemo alone 🧬 pCR = 95.3% survival 📉 ctDNA clearance = better outcomes ⚖️ Time to rethink neoadjuvant strategies   📚 Read in NEJM : A landmark in thoracic oncology! #LungCancer #Immuno...

🚨 New insights from EHJ 2025! 🚨   In statin-treated patients undergoing PCI, inflammation (hsCRP ≥2 mg/L) —not elevated LDL-C—was the strongest predictor of MACE at 1 year 🔥🧪   📊 Bay et al. show that residual inflammatory risk carries a 1.8x higher hazard for adverse events, while LDL-C alone showed no independent risk 💥   🧠 Time to shift focus beyond lipids: consider anti-inflammatory ther...

🔎 Averroes (Ibn Rushd, 1126–1198), the "Father of Rationalism," bridged Islam & the West through philosophy, medicine & law. 🌍 His commentaries on Aristotle, theory of the intellect, and medical insights (stroke, Parkinson's, retina) shaped centuries of thought. 📚 His legacy reminds us that reason, faith & science can coexist in pursuit of truth.   💡 #Philosophy #Medicine #History

🚨 New Study Alert 🧬🫀   Think a CAC score of zero means you're in the clear? Think again. A massive cohort from the Western Denmark Heart Registry (n = 23,777) shows that elevated LDL-C is strongly associated with non-calcified plaque 🧱 and future coronary events 💥—even in those with CAC = 0 .   📈 Each 1 mmol/L (~39 mg/dL) rise in LDL-C increases the odds of plaque (aOR 1.21) and risk of CHD...

🚨 New in NEJM 🫁: The IMPALA-2 trial shows that inhaled molgramostim significantly improves gas exchange, quality of life, and exercise capacity in patients with autoimmune pulmonary alveolar proteinosis (aPAP) —a rare disease driven by GM-CSF autoantibodies .   💨 Say goodbye to whole-lung lavage—this is a bench-to-bedside success story 30 years in the making. 🔬 From GM-CSF knockout mice ➡️ inh...

🚨 New Stroke Trial Alert! 🧠💉   Can IV alteplase help beyond the 4.5-hour mark? The HOPE trial (JAMA 2025) says YES —if perfusion imaging shows salvageable brain tissue 🧬🕑.   📊 Functional independence at 90 days improved from 26% ➡️ 40% , despite a small uptick in symptomatic ICH (3.8%).   🌍 Game-changer for patients in low-resource settings where thrombectomy isn't an option.   📖 Read more...